Abstract

Grifols SA will report quarterly results on February 26, 2026 before-market, with consensus pointing to year-over-year growth in revenue and adjusted EPS against mixed EBIT dynamics and an unchanged focus on execution in its core businesses.

Market Forecast

Consensus for the upcoming quarter implies total revenue of $2.01 billion, up 7.76% year over year, with adjusted EPS estimated at $0.253, up 16.25% year over year, and EBIT estimated at $363.00 million, down 3.27% year over year. Gross profit margin and net profit margin have not been guided by consensus, but the combination of revenue growth and higher EPS alongside a softer EBIT run-rate suggests expectations for favorable product mix, operating cost control, and non-operating tailwinds. The main business is expected to remain anchored by the company’s core commercial portfolio and contract activity, emphasizing volume stability and disciplined pricing tied to recent execution improvements. The most promising contribution remains aligned to the core revenue engine that generated $1.62 billion last quarter and is set to benefit from the projected 7.76% year-over-year increase in consolidated revenue.

Last Quarter Review

Grifols SA delivered revenue of $1.87 billion (up 4.04% year over year), a gross profit margin of 40.29%, GAAP net profit attributable to the parent company of $127.00 million, a net profit margin of 6.81%, and adjusted EPS of $0.21 (up 31.25% year over year). A notable highlight was operating profit outpacing sales growth, with EBIT of $383.27 million up 7.27% year over year, consistent with margin stabilization and tighter expense control through the period. Main business performance was concentrated in Biopharmaceuticals at $1.62 billion (86.82% of total revenue), while Diagnostics contributed $147.41 million (7.90%), Bio Supplies $38.88 million (2.08%), and Others $59.58 million (3.19%), collectively underpinning the 4.04% year-over-year increase in consolidated revenue.

Current Quarter Outlook

Biopharmaceuticals

Biopharmaceuticals remains the central driver of the company’s financial profile, and the forecasted step-up in total revenue to $2.01 billion indicates management and market expectations for continued commercial traction. The prior quarter’s gross margin of 40.29% provides a useful benchmark: while consensus does not publish a margin forecast, sustaining a 40% range would support incremental operating leverage if volumes scale as expected. The pattern of last quarter’s adjusted EPS rising faster than revenue suggests ongoing efficiency efforts and product-mix optimization can continue to convert top-line growth into bottom-line resilience. The sequential uplift embedded in the revenue estimate implies better throughput and steady demand in the quarter now being reported. If the company holds recent discipline on direct and indirect costs, the segment’s contribution should mitigate EBIT softness indicated by consensus, leaving EPS uplift supported by below-the-line items and mix. The main watchpoint is execution consistency: a repeat of last quarter’s operating cadence would likely keep gross margin close to the prior level and protect cash earnings despite the EBIT headwind in forecasts. With Biopharmaceuticals at $1.62 billion last quarter, it accounted for 86.82% of the company’s revenue base, amplifying its influence on consolidated outcomes. As such, even modest positive deltas in price or volume within this segment can materially impact reported EPS, particularly when SG&A and manufacturing overhead absorption are well-contained. The consensus mix of rising revenue and higher EPS despite lower EBIT suggests investors are prepared for a quarter where operating efficiency and financial line-items bridge any shortfall in core operating income.

Diagnostics

Diagnostics posted $147.41 million last quarter, accounting for 7.90% of consolidated revenue. The segment’s scale is smaller than the core franchise, but its contribution is increasingly relevant for blended margin quality and the stability of consolidated operating income, especially in quarters where EBIT is forecast to compress year over year. If Diagnostics maintains consistent revenue traction and cost discipline, it can help buffer variability from other lines and offer incremental support to consolidated gross margin. In the absence of published segment-level growth figures for the upcoming print, Diagnostics’ relevance in the outlook hinges on consistent throughput, predictable contract revenue recognition, and maintenance of cost controls that protect contribution margins. A flat to modestly positive performance here can be sufficient, given the company’s larger revenue engine is where the primary uplift is expected to come from this quarter. Given last quarter’s segment mix, a steady Diagnostics result should complement the core business and help preserve EPS resilience implied by consensus. Because consensus expects consolidated EPS to rise year over year while EBIT declines, smaller segments like Diagnostics can play an outsized role in smoothing quarter-to-quarter variability. The more consistent the Diagnostics line, the less pressure on the core business to overdeliver. That interaction may be critical for meeting or modestly exceeding EPS expectations if the top line lands near the $2.01 billion estimate.

Stock-price swing factors this quarter

The first swing factor is the relationship between revenue growth and operating profitability. Consensus embeds a 7.76% year-over-year increase in revenue but a 3.27% year-over-year decline in EBIT. If the company’s gross margin holds near the last quarter’s 40.29%, and if cost controls are visibly intact, investors may look through the EBIT softness and focus on EPS delivery, in line with the 16.25% year-over-year increase implied by estimates. The second swing factor is the conversion of operating results into per-share earnings. With last quarter’s adjusted EPS growth of 31.25% outpacing sales growth, investors will examine whether financial items such as interest expense, tax rate, or non-cash amortization dynamics help reconcile the forecast gap between EBIT and EPS. Any clarity on these items in management’s commentary can shape the sustainability debate around EPS growth if operating income lags. The third swing factor is segment mix and its implications for margin. Last quarter’s revenue mix was heavily skewed to Biopharmaceuticals at 86.82%, supporting scale benefits, while Diagnostics and other segments contributed margin diversity and stability. A revenue print aligned with the $2.01 billion estimate would likely require steady Biopharmaceuticals performance; if the mix favors higher-margin products within the segment, the market could reward the stock on evidence of quality growth. Conversely, if the composition skews toward lower-margin lines and EBIT compression is more acute than anticipated, valuation could respond negatively even if the top line meets expectations. A related factor is sequential cadence. The prior quarter produced $1.87 billion of revenue and a $127.00 million GAAP net profit with a 6.81% net margin, aided by what the quarter-to-quarter run-rate signaled as healthy execution. Investors will parse whether the company can translate the expected sequential revenue improvement into stable gross margin and contained operating cost growth. Delivering on the EPS estimate while demonstrating cost discipline would validate the consensus view; missing either would challenge the constructive bias implied by estimates. Finally, disclosure clarity around non-operating items could be decisive. With EBIT forecast to decline year over year but EPS to increase, the bridge through interest, tax, and other below-the-line items will need to be explicit for the market to maintain confidence in the earnings algorithm. A clean and transparent reconciliation would help investors assess the repeatability of EPS growth into subsequent quarters.

Analyst Opinions

Bullish-to-bearish commentary identified within the covered period is limited, and explicit brokerage previews specific to the company’s upcoming results were not evident. The observable majority stance aligns with the constructive tilt implied by consensus estimates: rising revenue and adjusted EPS expectations alongside contained operating income shape a cautiously positive narrative into the print. In practical terms, that places the weight of opinion on an outlook where the company meets or modestly beats the top-line estimate and converts that into EPS delivery through mix and financial-line support. This majority view emphasizes three points. First, the consolidation of last quarter’s operating improvements sets a workable base: a 40.29% gross margin and a $383.27 million EBIT demonstrate that operating structure can sustain growth, even if the year-over-year EBIT comparison softens this quarter. Second, the earnings model’s sensitivity to mix and non-operating items means EPS can rise faster than revenue, which is reflected in the 16.25% year-over-year EPS growth estimate against a 7.76% revenue growth estimate. Third, segment concentration is well understood by the market; if the core revenue engine stays intact, the smaller segments do not need to overperform to allow the group to meet consensus EPS. The constructive majority also notes that visibility into the reconciliation from EBIT to EPS will be pivotal in shaping post-print reaction. A clear bridge that shows disciplined interest expense, an efficient tax rate, or a benign mix of non-cash items would validate the current consensus position. Given the prior quarter’s outturn — adjusted EPS growth outpacing revenue growth and GAAP net profit reaching $127.00 million — expectations are set for a quarter where management demonstrates continuity rather than step-change acceleration. In the absence of widespread, dated brokerage notes within the specified window, market participants appear to lean on the consensus trajectory as the guiding signal. That perspective is inherently balanced: it expects improvement in revenue and EPS without extrapolating aggressive operating margin expansion. Should the company meet the $2.01 billion revenue estimate and deliver EPS near $0.253, this majority stance would be affirmed; stronger-than-expected operating leverage would tilt sentiment more positive, while a disappointment in mix or below-the-line dynamics would challenge the current constructive bias.